The DCIS that recurred was significantly more likely to express moderate to strong (2 to 3+) levels of cytoplasmic survivin (76%) compared to 37% of nonrecurrent disease (P=0.0001) (Table 1). This evidence concerns the gene BIRC5 and ductal breast carcinoma in situ.